Compare AstraZeneca plc (AZN) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs NetApp Inc. — how do they compare? AstraZeneca plc trades at $168.14 (market cap $253.13B), while NetApp Inc. trades at $162.11 (market cap $34.20B). The key difference: AstraZeneca plc is far larger — about 7.4× NetApp Inc.'s market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | NTAP | |
|---|---|---|
Market Cap | $253.13B | $34.20B |
Sector | Health | Technology |
52-Week High | $209.48 | $181.08 |
52-Week Low | $137.44 | $94.11 |
Enterprise Value | $279.37B | $33.35B |
Dividend Yield | 1.92% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
NetApp (NTAP) trades at $163.93, down 2.93% on the day, but maintains a bullish technical stance with strong moving averages and support near $162. The company demonstrates robust fundamentals with a 70.74% gross margin and consistent earnings beats, including Q1 2026 EPS of $2.43 versus $2.27 expected. Recent news highlights AI-driven growth opportunities, such as StorageGRID 12.1 enhancements for AI workloads announced on June 23, 2026.
Outlook remains positive with analyst consensus target at $167.45, offering modest upside. Key opportunities include enterprise AI demand and all-flash storage adoption, while risks involve competitive pressures and debt levels rising to 29.89% of assets. The stock's valuation at a P/E of 25.82 warrants monitoring amid sector comparisons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
